• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sean Whooley

Eyenovia unveils digital ocular drug delivery device

December 22, 2022 By Sean Whooley

Eyenovia microdose array print MAP ocular drug delivery device

Eyenovia (Nasdaq:EYEN) announced today that it is developing a microdosing system to facilitate the digital delivery of eye medications. New York-based Eyenovia develops a pipeline of late-stage microdose array print (MAP) therapeutics. It aims for this system to improve the overall patient experience and streamline practice flow. The investigational device showed promise in delivery cleaner […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic, Technology Tagged With: Eyenovia Inc.

FDA clearance for Dexcom G7 marks a ‘huge leap’ forward, COO Jake Leach says

December 21, 2022 By Sean Whooley

Dexcom G7

After plenty of anticipation — and a bit of waiting — the next-generation Dexcom G7 continuous glucose monitor is finally here. In mid-2021, Dexcom (Nasdaq:DXCM) CEO Kevin Sayer told Drug Delivery Business News that its next-generation CGM would be “wonderful.” At the time, he said enthusiasm over the Dexcom G7 sat at an all-time high. About […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Regulatory/Compliance, Technology Tagged With: CGM, Dexcom

Abbott FreeStyle Libre 3 links with automated insulin delivery system for use in Europe

December 21, 2022 By Sean Whooley

Abbott FreeStyle Libre 3 sensor pennies CGM diabetes

Abbott (NYSE:ABT) today announced compatibility between its FreeStyle Libre 3 sensor and the mylife Loop from Ypsomed and CamDiab. Combined, the technologies create a smart, automated process for insulin delivery based on real-time glucose data. The companies launched their automated insulin delivery (AID) system in Germany. They intend to offer it in additional European countries […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, CamDiab, Ypsomed

Embecta stock slides on mixed Q4 results

December 20, 2022 By Sean Whooley

BD Diabetes Spinoff Embecta

Embecta (Nasdaq:EMBC) shares dipped today on fourth-quarter results that came in mixed compared to the consensus forecast. EEMBC shares fell more than 12% to $29.73 apiece in morning trading. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up more than 4%. The Parsippany, New Jersey-based company posted losses […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: BD, embecta

Amalgam Rx, Novo Nordisk expand partnership on connected insulin delivery devices

December 19, 2022 By Sean Whooley

Amalgam Rx Novo Nordisk Dose Check partnership

Amalgam Rx announced today that it expanded its global agreement with Novo Nordisk over the commercialization of Dose Check. Wilmington, Delaware-based Amalgam Rx develops the Dose Check digital insulin initiation and titration app. It designed the app to help people with type 2 diabetes using basal insulin. The two companies partnered to incorporate and integrate […]

Filed Under: Auto-injectors, Big Data, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: amalgamrx, Novo Nordisk

Analysts remain neutral on Embecta, await insulin patch pump developments

December 16, 2022 By Sean Whooley

BD Diabetes Spinoff Embecta

BTIG analysts maintained their neutral rating for Embecta (Nasdaq:EMBC) ahead of the company’s fourth-quarter earnings report next week. Embecta, the BD diabetes spinoff, reports its fourth-quarter earnings on Tuesday, Dec. 20. Analysts Marie Thibault and Sam Eiber also expect 2023 guidance to come from management then. The analysts mainly expect the patch pump market to […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: BD, embecta

Insulet COO announces intent to retire

December 15, 2022 By Sean Whooley

Insulet EVP COO Charles Chuck Alpuche

Insulet (Nasdaq:PODD) issued an SEC filing confirming that Charles Alpuche, executive vice president and chief operating officer, intends to retire. Alpuche informed the company of his decision to retire on Dec. 13. His retirement takes effect on Dec. 31, 2022. The Acton, Massachusetts-based automated insulin delivery technology developer promoted Prem Singh as a result. Singh […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Personnel Tagged With: Insulet, Personnel Moves

Interim data supports Vaxess shelf-stable flu vaccine patch

December 14, 2022 By Sean Whooley

Vaxess Technologies MIMIX vaccine patch

Vaxess Technologies today announced positive interim results from a first-in-human trial of its influenza vaccine patch. Cambridge, Massachusetts-based Vaxess evaluated VX-103, a monovalent seasonal influenza vaccine patch. The trial included 45 healthy patients and evaluated the H1N1 influenza antigen from Vaxess’ partner, GC Biopharma. Delivery of the vaccine took place through the Vaxess Mimix patch. […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Vaxess Technologies

FDA accepts NDA for over-the-counter Narcan nasal spray from Emergent BioSolutions

December 14, 2022 By Sean Whooley

Emergent Biosolutions Narcan

Emergent BioSolutions (NYSE:EBS) recently announced that the FDA accepted for review its over-the-counter Narcan (naloxone HCI) nasal spray. The FDA last week accepted Emergent’s supplemental new drug application (sNDA) for the Narcan opioid overdose emergency treatment. It also granted the application priority review. If approved, it would represent the first 4 mg naloxone nasal spray […]

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: Emergent BioSolutions, FDA

Evonik invests in Allay Therapeutics to reduce need for opioids

December 13, 2022 By Sean Whooley

Allay Therapeutics Evonik

Evonik announced today that it invested in Allay Therapeutics and its implant for treating pain after knee surgery. Inserted directly into the knee, the Allay implant may relieve pain for up to three weeks, according to a news release. Previous solutions worked for a maximum of three days, the company said. The technology helps promote […]

Filed Under: Business/Financial News, Drug-Device Combinations, Implants, Orthopedics Tagged With: Allay Therapeutics, Evonik

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 80
  • Page 81
  • Page 82
  • Page 83
  • Page 84
  • Interim pages omitted …
  • Page 174
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS